A Phase 2 Study of Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia

Trial Profile

A Phase 2 Study of Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Dec 2017

At a glance

  • Drugs Tipifarnib (Primary)
  • Indications Chronic myelomonocytic leukaemia
  • Focus Therapeutic Use
  • Sponsors Kura Oncology
  • Most Recent Events

    • 10 Dec 2017 According to a Kura Oncology media release, data from the study was presented at the American Society of Hematology (ASH) Annual Meeting and Exposition.
    • 10 Dec 2017 Status changed from recruiting to active, no longer recruiting, according to a Kura Oncology media release.
    • 01 Nov 2017 According to a Kura Oncology media release, data from the study will be presented at the American Society of Hematology (ASH) Annual Meeting and Exposition.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top